Denali Therapeutics Inc., discovers, develops, and delivers barrier-crossing therapeutics for neurodegenerative, lysosomal, and other serious diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; DNL921 Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics Inc.

Denali Therapeutics ( ($DNLI) ) has shared an update. On December 9, 2025, Denali Therapeutics entered into an underwriting agreement with major fi...

Denali Therapeutics Announces $200M Public Offering

Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Denali Therapeutics today and set a price target of $37.00. Matteis covers the Heal...

Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Pharmaceuticals (ARWR – Research Report)...

Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR), Cytokinetics (CYTK) and Denali Therapeutics (DNLI)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Denali Therapeutics yesterday and set a price target of $32.00. The company’s shares...

H.C. Wainwright Keeps Their Buy Rating on Denali Therapeutics (DNLI)

In a report released yesterday, Mayank Mamtani from B. Riley Securities maintained a Buy rating on Denali Therapeutics, with a price target of $30....

B. Riley Securities Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Denali Therapeutics, with a price target of...

Market Cap	$2.44B	P/E Ratio	N/A
52W High	$26.18	52W Low	$10.57
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-2.5%	52W Position	47.5%
Overall Score	63	Value Score	60
Quality Score	55	Technical Score	75

EPS Current Est	$-3	EPS Next Est	$-3.1
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNLI	$17.98	+3.51%	1.40M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DNLI	$17.98	+3.5%	1.40M
3
4
5
6

DNLI

DNLI

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Denali Therapeutics Inc. Data in Excel

Get Denali Therapeutics Inc. Data in Excel